News

NorInvent applies for delisting and writes down patent value

NorInvent AB (“NorInvent”) has announced that the Board has decided to apply for delisting from AktieTorget. The decision has been taken in consultation with AktieTorget, and is based on the fact that the company’s operations currently consists of basic research. For a more detailed description of the background, refer to the previous press release “Consequences […]

Read more

Board member Ingela Stenberg resigns from the board

NorInvent AB (“NorInvent”) has announced that Board member Ingela Stenberg has decided to resign from the board. Ingela Stenberg, with expertise in patent matters, states that her resignation is due to that NorInvent has now received Notice of Allowance in the United States and an Intention to Grant from the EU regarding the company’s patent […]

Read more

Consequences of lost documentation and status and what will happen in the future

NorInvent AB’s (“NorInvent”) share has been stalled since 9 April 2018 at 09.00. In order to clarify the company’s status NorInvent hereby publishes an update on how the company is affected by the lack of documentation regarding XtriG and how it affects the company in the future. The list below contains the most important information […]

Read more

CEO Paul Hasselgren has decided to leave his position

Paul Hasselgren has decided to leave his position but remains as CEO during his period of notice (six months). A withdrawal can take place earlier if a new CEO is employed before the end of the notice period. This information is information that NorInvent AB is obliged to make public pursuant to the EU Market […]

Read more

Intention to grant for the XtriG-patent in Europe

Today, NorInvent was informed that the European Patent Office that the EPO had communicated an Intention to grant, which means that the patent will be granted in Europe. NorInvent develops XtriG, the Company’s patented Drug Delivery platform for pharmaceutical uptake via the oral mucosa. XtriG aims at providing pharmaceutical companies with a means to give […]

Read more

Lost documentation from the founder’s research

The company cannot receive documentation from the founder’s research. Background NorInvent’s patented technology is based on Dr. Jonatan Moses’ previous research in the 1990s and early 2000s. Circumstances during the first months of the year are such that the company’s board of directors and management now judge that it is not probable that the documentation […]

Read more

Notice of Allowance for XtriG patent in the USA

The status for the company’s patent application has been updated to “Allowed”, which means that USPTO intends to grant the XtriG patent. NorInvent develops XtriG, the Company’s patented Drug Delivery platform for pharmaceutical uptake via the oral mucosa. XtriG aims at providing pharmaceutical companies with a means to give their existing drugs enhanced properties, such […]

Read more

Clarification of a previous press release concerning Proof of Mechanism

Following further analysis of data, the company deems that there may be a risk that the information in a previous press release can be misinterpreted due to the term “Proof of Mechanism”. The information is clarified by adding that the result that was presented is from a successful release study and that additional studies remain […]

Read more

Status update for development plans

New schedule for XtriG synthesis and better use of resources by postponement of toxicology studies. Previously, it was informed in the listing memorandum that the company intended to produce synthetic XtriG and to carry out toxicological studies in vitro and in vivo in 2017. These activities have not yet been carried out. Binding Studies and […]

Read more

Conversion to shares registered with the Swedish Companies Registration Office

NorInvent converts loans and increases the number of shares by 642 000 to a total of 14 940 686. As previously announced in the listing memorandum, the company had implemented a convertible loan of SEK 1,500,000, with a maturity up to December with an interest rate of 7% for the period and a conversion price of SEK 2.50 […]

Read more